Does Humana Cover Losartan? Formulary Tiers, Prior Auth, and Appeals

What Losartan Is and Why Insurers Cover It

Losartan is an angiotensin II receptor blocker (ARB) approved by the FDA in 1995 under the brand name Cozaar. Its labeled indications include hypertension, diabetic nephropathy in patients with type 2 diabetes and proteinuria, and reduction of stroke risk in patients with left ventricular hypertrophy (LVH) [1]. The American Heart Association and ACC 2023 Hypertension Guideline list ARBs, including losartan, as first-line therapy alongside ACE inhibitors, thiazide diuretics, and calcium channel blockers [2].

Generic losartan potassium has been available since 2010. Because the generic costs pharmacies roughly $2 to $8 per 30-day supply at acquisition, nearly every commercial formulary in the United States places it on Tier 1 or Tier 2. The FDA's Orange Book confirms generic bioequivalence for tablets from more than a dozen manufacturers [3]. That low acquisition cost is the single biggest reason Humana does not routinely require prior authorization for losartan in hypertension, even on its most restrictive commercial formularies.

Clinically, the LIFE trial (Lancet 2002, N=9,193) demonstrated that losartan 50 to 100 mg daily reduced the composite of cardiovascular death, stroke, and myocardial infarction by 13% compared with atenolol 50 to 100 mg over a mean follow-up of 4.8 years, with a statistically significant 25% reduction in fatal and nonfatal stroke (P<0.001) [4]. The RENAAL trial (N=1,513) showed losartan 100 mg daily reduced the risk of doubling serum creatinine, end-stage renal disease, or death by 16% in patients with type 2 diabetes and nephropathy compared with placebo (P=0.02) [5]. These outcomes data underpin guideline support and, by extension, insurer willingness to cover the drug without restriction.

What Formulary Tier Is Losartan on Humana?

On most Humana commercial (employer-sponsored) and individual ACA plans, generic losartan sits at Tier 1, the lowest cost-sharing tier, with copays between $0 and $15 for a 30-day supply. A minority of commercial contracts place it at Tier 2, carrying copays of $15 to $40 [6]. Brand-name Cozaar, where it still appears on formulary at all, typically lands at Tier 3 or Tier 4, with copays of $50 to $90 or coinsurance of 30% to 50%.

Humana Medicare Advantage (MA) plans operate under CMS-approved formularies that are contract-specific and can change each plan year. CMS Part D data for 2024 show that among the roughly 900 Humana MA-PD contracts, over 78% include generic losartan at Tier 1 or Tier 2 with no restrictions [7]. The remaining contracts may apply step therapy or quantity limits, particularly for doses above 100 mg per day. Checking the exact plan using the Medicare Plan Finder at medicare.gov or calling 1-800-HUMANA is the most reliable method before prescribing or filling.

The low-income subsidy (LIS), sometimes called Extra Help, eliminates or sharply reduces the copay for losartan on any Part D-covered Humana plan. In 2024, full-LIS beneficiaries pay no more than $4.50 for Tier 1 generics [8]. Patients qualifying for LIS and denied coverage on that basis have grounds for an immediate formulary exception.

Does Humana Require Prior Authorization for Losartan?

For the hypertension indication, Humana commercial plans almost never require prior authorization (PA) for generic losartan. The drug's generic status, low cost, and first-line guideline placement make a PA requirement economically irrational for the insurer.

Humana MA plans are more varied. PA may be required in three specific scenarios: (1) the prescriber requests a dose above the plan's quantity limit (for example, more than 100 mg daily), (2) the listed indication is diabetic nephropathy or HFrEF rather than straightforward hypertension, or (3) the plan has designated losartan as subject to step therapy requiring evidence that another antihypertensive was tried first [9]. A 2022 analysis published in the Journal of Managed Care and Specialty Pharmacy found that ARBs were subject to prior authorization in 14% of sampled Medicare Part D plan formularies, compared with only 4% of commercial formularies [10].

When PA is required, Humana's standard criteria for ARBs typically include: a confirmed diagnosis (ICD-10 I10 for hypertension, N18.3, N18.6 for CKD with proteinuria, or I50.x for heart failure), documented intolerance or contraindication to ACE inhibitors if the plan uses step therapy, and a note from the prescriber confirming the clinical rationale. Submitting all three elements in the initial PA request reduces denial rates substantially.

The ACC and AHA note in their 2022 Guideline for Heart Failure that "ARBs are recommended for patients with HFrEF who cannot tolerate ACE inhibitors" (Class I, Level of Evidence A) [11]. Including that guideline citation in the PA letter often accelerates approval.

Does Humana Use Step Therapy Before Losartan?

Step therapy for losartan on Humana plans is uncommon but not rare. When it appears, the required first-step agent is usually a thiazide diuretic (most often hydrochlorothiazide 12.5 to 25 mg) or a calcium channel blocker (amlodipine 5 to 10 mg). These agents are even cheaper than losartan, so the insurer's rationale is cost, not clinical inferiority.

The 21st Century Cures Act (enacted 2016, regulations finalized 2018) requires that MA plans grant a step therapy exception when: the required first-step drug is contraindicated, the patient previously tried and failed the step drug, or the patient is clinically stable on the requested drug and switching would likely cause harm [12]. Physicians should document any of these conditions explicitly in the exception request.

For patients with diabetic nephropathy, step therapy toward a non-ARB agent is harder for a plan to defend given the RENAAL data [5] and the ADA's Standards of Medical Care in Diabetes 2024, which state: "For patients with diabetes and hypertension with CKD and urinary albumin-to-creatinine ratio 300 mg/g or greater, an ACE inhibitor or ARB is recommended" [13]. Citing that specific ADA recommendation in the step therapy exception request routinely satisfies Humana's clinical criteria.

HealthRX Step-Therapy Exception Framework for Losartan on Humana MA Plans

Use this sequence when a Humana MA plan imposes step therapy before losartan:

1. Confirm the exact step-therapy requirement by calling Humana Provider Relations (the number appears on the plan's EOB or at humana.com/provider).
2. Identify which 21st Century Cures exception applies (contraindication, prior failure, or stability/harm).
3. Attach clinical notes, labs (urine albumin-to-creatinine ratio, eGFR, potassium), and the relevant guideline citation.
4. Submit via Humana's online portal or fax the PA form with exception language within 24 hours of diagnosis or patient contact.
5. If denied, escalate immediately to internal appeal within the same business day to preserve the 72-hour expedited timeline.

How to Appeal a Humana Denial of Losartan

Humana denials for losartan follow two different appeal tracks depending on the plan type.

Commercial plan denial. Humana must acknowledge an internal appeal within 15 calendar days and resolve it within 30 days for standard appeals, or 72 hours for expedited appeals when delay would "seriously jeopardize the enrollee's life, health, or ability to regain maximum function" (CMS codified standard, 45 CFR 147.136) [14]. Supply the denial letter, the prescriber's clinical notes, and the relevant AHA/ACC or ADA guideline passage. If the internal appeal fails, request an external review through the applicable state insurance commissioner or the Federal External Review Program under the ACA.

Medicare Advantage denial. The MA appeals process has five levels: (1) plan-level redetermination (60 days to file, 7-day standard or 72-hour expedited decision), (2) Independent Review Entity (IRE) reconsideration conducted by MAXIMUS Federal Services (the CMS-contracted IRE), (3) Office of Medicare Hearings and Appeals (OMHA) if the amount in controversy exceeds $180 in 2024, (4) Medicare Appeals Council, and (5) federal district court [15]. For a 30-day losartan supply worth approximately $10 to $15, the amount-in-controversy threshold for OMHA is rarely met. The IRE level (MAXIMUS) is therefore the practical ceiling for most losartan coverage disputes.

CMS data from 2022 show that approximately 43% of Part D coverage determination appeals decided by IRE were resolved in favor of the beneficiary [16]. The single most influential factor in reversal is a physician-authored letter that matches the denial reason and cites a specific clinical guideline, trial, or FDA-approved indication. Generic appeals without clinical specificity are overturned at a significantly lower rate.

When submitting to MAXIMUS, use the CMS-10280 Redetermination Request form and attach: the original denial notice, the most recent office visit note, relevant labs (creatinine, eGFR, urine albumin), and a one-page cover letter from the prescriber. MAXIMUS accepts fax at 1-833-919-0198 and online submission at mymedicare.gov.

Humana Formulary Exception: When the Drug Is Not on the Plan's List

A small fraction of Humana MA plans use a "closed formulary" model that excludes losartan entirely in favor of a different ARB, such as valsartan or olmesartan. In that case, the appropriate pathway is a formulary exception rather than a standard appeal.

To request a formulary exception, the prescriber must document that the listed ARBs are "not therapeutically equivalent" or are "contraindicated." Differential tolerability (for example, documented leg edema with amlodipine that resolved on losartan) satisfies this standard under 42 CFR 423.578 [17]. The plan must respond to a formulary exception request within 72 hours (standard) or 24 hours (expedited).

A 2021 JAMA Internal Medicine analysis found that formulary exception approval rates varied from 23% to 89% across Part D plans, with physician-submitted requests approved roughly 2.3 times more often than patient-only submissions [18]. Co-signing the request with a supervising physician meaningfully improves approval odds.

Cash-Pay and Savings Card Alternatives While Appealing

While an appeal is in progress, patients should not go without losartan. Cash-pay options are inexpensive.

GoodRx lists generic losartan 50 mg, quantity 30, at $9 to $14 at Walmart, Costco, and Kroger pharmacies as of mid-2025 [19]. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists losartan 100 mg, 30 tablets, at $7.40, without insurance or membership requirements.

Manufacturer savings cards for brand Cozaar are available through the Merck Patient Assistance program, but CMS regulations under 42 CFR 423.104(e)(1) prohibit using manufacturer copay cards to satisfy Part D cost sharing [20]. Using a copay card on a Medicare plan can therefore count as inducement under the Anti-Kickback Statute and may not be legally used by the pharmacy. Cash payment through a discount card (GoodRx, RxSaver, NeedyMeds) is the compliant workaround for Medicare beneficiaries; these are treated as cash transactions outside the Part D benefit.

For patients below 250% of the federal poverty level, the Merck Patient Assistance Program (PAP) can supply brand Cozaar at no cost. The application is at merck.com/merckhelps. Processing takes 10 to 14 days and requires income documentation.

Clinical Context: What Doses and Indications Matter for Coverage

Dose matters to Humana's quantity limits. Most plans cover losartan up to 100 mg daily (one 100-mg tablet or two 50-mg tablets) without restriction. Doses above this threshold, which are occasionally used off-label in resistant hypertension or high-proteinuria CKD, trigger automatic quantity-limit review and may require PA [9].

The FDA-approved dosing for losartan in hypertension is 25 to 100 mg once daily, with a maximum of 100 mg per day [1]. For diabetic nephropathy, the RENAAL protocol used 50 mg titrated to 100 mg daily; the FDA label reflects this range [5]. Heart failure dosing starts at 12.5 to 25 mg daily and can be titrated to 150 mg daily, a dose above the standard quantity limit on most Humana plans and therefore almost always requiring PA in the HFrEF setting.

The 2022 ACC/AHA/HFSA Guideline for Heart Failure specifies a target ARB dose equivalent to losartan 150 mg daily for HFrEF [11]. That guideline reference, combined with documentation of ACE-inhibitor intolerance (most often cough, which occurs in 10% to 20% of ACE inhibitor users per a 2020 Cochrane review involving 35 trials) [21], forms the core clinical argument for PA approval at higher doses.

Losartan has no FDA-approved indication for weight loss. CMS explicitly excludes weight-loss medications from Medicare Part D coverage under 42 USC 1395w-102(e)(2) [22]. A small number of investigational studies have examined ARBs and adipokines, but no regulatory authority has approved losartan for obesity. Prescribers submitting a PA listing weight loss as the primary indication can expect denial; the prescription must be anchored to an approved indication to be covered.

Monitoring Requirements That Support the Coverage Argument

Humana's PA and formulary exception reviewers respond favorably to documentation showing appropriate clinical monitoring. For losartan, standard monitoring includes serum potassium, serum creatinine, and blood pressure at baseline and at 2 to 4 weeks after initiation or dose change [2]. In CKD patients, the ADA recommends monitoring eGFR and urine albumin-to-creatinine ratio at least annually [13].

Including recent lab values in the PA submission demonstrates that the prescriber is following evidence-based practice and reduces the plan's concern about inappropriate use. A chart note showing potassium below 5.0 mEq/L, creatinine stable, and blood pressure at or approaching the AHA's goal of below 130/80 mmHg [2] signals appropriate management and reduces the perceived need for insurer intervention.

Drug interactions also affect coverage decisions indirectly. Losartan combined with a potassium-sparing diuretic or another ARB raises hyperkalemia risk [23]. If a plan reviewer sees a medication list with both losartan and spironolactone (a common HFrEF combination), the PA note should acknowledge the rationale and monitoring plan. The 2022 ACC/AHA/HFSA guideline endorses this combination under defined conditions [11], so documenting guideline concordance matters.

What to Expect at the Pharmacy Counter

A patient presenting a losartan prescription at a Humana in-network pharmacy will typically see one of three outcomes: (a) immediate fill at the Tier 1 or Tier 2 copay, (b) a message that PA is required, or (c) a message that the drug is not covered (formulary exclusion).

For outcome (b), the pharmacy should transmit the PA request electronically to Humana CoverMyMeds or call Humana Pharmacy at 1-800-379-0092. Turnaround for non-urgent PA on a generic antihypertensive is usually same day to next business day. The prescriber's office can check status at humana.com/prior-authorization.

For outcome (c), the pharmacist is required under CMS rules to provide the patient with a written notice of the formulary exclusion and the plan's exception process [24]. Ask for that notice; it is the starting document for any formulary exception or appeal.

If the prescriber's office does not respond to the PA request within 24 hours, the patient can self-pay the cash price (approximately $10) and request reimbursement retroactively after a successful appeal. CMS requires MA plans to reimburse cost-sharing paid out of pocket when an appeal is decided in the enrollee's favor [15].